Our observations correlate with many prior studies and suggest that BCP could be used as a safe prophylactic nephroprotective substance against nephropathy associated with AK treatment by downregulating NF-κB and TGF-β1 and simultaneously enhancing antioxidative mechanisms by upregulating Nrf2-regulated molecules in renal tissues [15, 50–52, 54, 55]. Here, NFE2L2 is linked to kidney disorder.